What Has Changed About Owning Eli Lilly Stock?
Eli Lilly (LLY) reported a 75.3% return over the past year, outperforming the S&P 500. Its Q3 2026 report showed a shift in spending, with $19.0B on capital projects exceeding $15.4B on R&D for the year. This marks the first time since 2011 that capital spending surpassed research. The company is investing in new manufacturing sites, including a $6.5B facility in Houston, to support growth of drugs like Mounjaro and Zepbound, which generated over $16B in Q3 revenue.
How this was made
The 30-second read
Why it matters
Investors will weigh the trade‑off between accelerated manufacturing capacity and potential slowdown in pipeline development.
Market read
The disclosed capex‑R&D reversal is a material corporate development that could influence valuation and sector sentiment.
What to watch
The company still increased absolute R&D spend year‑over‑year, and new facilities may be critical for meeting demand for Mounjaro and Zepbound.
Background
Eli Lilly's Q3 2026 earnings highlighted a strategic shift in capital allocation, with capex now outpacing R&D for the first time in over a decade.
Ticker impact
Eli Lilly reported capital spending of $19.0B exceeding R&D $15.4B in the twelve months to Sep 30, 2026 – first time R&D fell below capex since 2011.
potential downside pressure as the market prices in reduced R&D investment
Large‑scale capital allocation change is material; investors typically favor sustained R&D spend for long‑term pipeline strength.
Market effects
Signals a possible industry trend of pharma firms prioritizing manufacturing capacity, which could affect peers' capex expectations.
U.S. biotech sector may see modest re‑rating as investors reassess R&D intensity metrics.
Limited to large‑cap pharma; unlikely to move broader markets.
Counterpoint
Higher capex could enable faster product rollout and margin expansion, offsetting concerns about lower R&D.
Key entities
- CompanyEli Lilly
U.S. pharmaceutical company (ticker LLY) reporting Q3 2026 results.
